Paclitaxel-containing aminoester phosphate 4 and phosphoamidate 9 were synthesised and found to possess anticancer activity against HL-60 leukemia cells; their solubility in a phosphate buffer solution was about 16 times higher than that of paclitaxel.
Paclitaxel 1 is one of the most promising anticancer agents; 1 it inhibits cell division and other interphase processes by stabilising microtubules. [2] [3] [4] [5] [6] This anticancer agent has an extremely low solubility in water. 4, 5 Thus, enormous efforts have been focused on the modification of paclitaxel in order to create more watersoluble and, consequently, more easily formulated and delivered drugs. 7 New paclitaxel derivatives could be designed to convert, in a predictable fashion, into the original active drug by either an enzymic mechanism [8] [9] [10] [11] [12] or simple hydrolysis initiated under physiological pH conditions. 13 Most accounts to date for paclitaxel 1 have been concerned with its esterifications at the C-2' 7,11,14-21 or C-7 11, [22] [23] [24] [25] hydroxyl group for improvement of the water solubility while the cytotoxic activity is maintained. 7, [14] [15] [16] [17] [18] [19] [21] [22] [23] 25 In general, dephosphorylation occurs easier in cancer cells than in normal cells. Thus, chemotherapeutic agents possessing a phosphate or phosphoamidate unit would preferentially interact with the cancer cells. 26 Given these phenomena, we designed and synthesised new paclitaxel-containing aminoester phosphate 4 (Scheme 1) and phosphoamidate 9 (Scheme 2) 27 with higher water solubility. These new propaclitaxel analogues were found to possess anti-leukemic activity slightly greater than that of paclitaxel.
To synthesise 2'-[4-(N,N-dimethylammonium)butyryl]paclitaxel 7-phosphate 4, we condensed paclitaxel 1 with 4-(N,N-dimethylamino)butyric acid 2 in the presence of dicyclohexylcarbodiimide (DCC) and a catalytic amount of (dimethylamino)pyridine (DMAP) in CH 2 Cl 2 at 25°C (Scheme 1). † Corresponding amino ester 3 was obtained in 88% yield. The reaction of 3 with P(OMe)Cl 2 in the presence of collidine in THF at 0°C and then with I 2 and water at 25°C produced the target compound, ammonium ester phosphate 4, in 90% yield. 27 Compound 4 existed in its zwitterionic form.
For the preparation of 2'-[3-(phosphoamido)propionyl]paclitaxel 9, we treated paclitaxel 1 with 3-(N-monomethoxytritylamino)propionic acid 6 in the presence of DCC and DMAP in CH 2 Cl 2 at 25°C to give monomethoxytritylated amino ester 7 in 95% yield (Scheme 2). ‡ Compound 7 in wet acetonitrile was treated with a catalytic amount of ceric ammonium nitrate (CAN) at 25°C to afford detritylated amino ester 8 in 97% yield. 28 The reaction of 8 with P(OMe)Cl 2 and collidine in THF and then with I 2 and water produced desired phosphoamidate 9 in 85% yield. 27 The solubility (µmol dm -3 ) in a phosphate buffer solution (0.10 M, pH 6.5) was 896 for 4, 952 for 9 and 57.8 for paclitaxel 1. Paclitaxel-containing aminoester phosphate 4 and phosphoamidate 9 were tested in vitro against HL-60 leukemic cells. 29, 30 The IC 50 values (µmol dm -3 ) were 4.0×10 -3 for 4, 3.8×10 -3 for 9 and 4.5×10 -3 for 1.
In comparison with paclitaxel 1, new compounds 4 and 9 were found ~16 times more soluble in a phosphate buffer solution, and they exhibited comparable anti-leukemic activities in vitro. The free C(2')-OH group is essential for the anticancer activity of paclitaxel. 27 Therefore, hydrolysis of the ester component in 4 and 9 under physiological pH conditions to give 5 and 1, respectively, is responsible for the anti-leukemic activity of these new paclitaxel derivatives. On the other hand, the C(7)-phosphate functionality in 5 cannot be hydrolysed in vitro where phosphoesterases are not present. Thus, the C(7)-phosphate derivative of paclitaxel (i.e., 5) possesses anti-leukemic activity comparable with that of paclitaxel 1. 
